Thus, an important question that arose during this study was whether patients with higher serum CRP (i.e., ⩾30 mg l–1) had been given an insufficient siltuximab dose to suppress their IL-6 levels adequately to achieve a tumour response. This evidence concerns the gene CRP and neoplasm.